@article {935686,
	title = {The Efficacy and Safety Profile of Ocriplasmin in Vitreomacular Interface Disorders.},
	journal = {Semin Ophthalmol},
	volume = {32},
	number = {1},
	year = {2017},
	pages = {52-55},
	abstract = {Vitreomacular adhesion (VMA) describes the adhesion of the posterior hyaloid face to the inner retina in any part of the macula. This can arise after incomplete separation of the posterior vitreous cortex from the macula during vitreous liquefaction. While the VMA may resolve spontaneously, a strong and persistent adhesion can lead to a variety of anatomical changes, including vitreomacular traction (VMT) and macular hole (MH). Both conditions can present with metamorphopsia and decreased vision. In cases of symptomatic VMT and full-thickness macular hole, pars plana vitrectomy has long been the standard of care. However, due to the possible surgical complications and need for postoperative care, many have searched for non-surgical options via pharmacologic vitreolysis. Ocriplasmin (Jetrea, Thrombogenics USA, Alcon/Novartis EU) is a recombinant protease approved in October 2012 for the treatment of symptomatic vitreomacular adhesion (VMA). There have been conflicting views on the safety of Ocriplasmin with changes in the ellipsoid zone seen on OCT and changes seen on ERG indicating photoreceptor damage. This publication reviews the efficacy and safety of ocriplasmin injection for VMA based on previously published data.},
	issn = {1744-5205},
	doi = {10.1080/08820538.2016.1228416},
	author = {Shaikh, Mehrine and Miller, John B and Papakostas, Thanos D and Husain, Deeba}
}
